Combination chemotherapy of imatinib, vinblastine, and prednisolone in a dog with cutaneous mast cell tumor: Evaluation of treatment response with 18F-fluorodeoxyglucose positron emission tomography.
Sejung Ahn, Yeon Chae, Taesik Yun, Hakhyun Kim, Byeong-Teck Kang
{"title":"Combination chemotherapy of imatinib, vinblastine, and prednisolone in a dog with cutaneous mast cell tumor: Evaluation of treatment response with <sup>18</sup>F-fluorodeoxyglucose positron emission tomography.","authors":"Sejung Ahn, Yeon Chae, Taesik Yun, Hakhyun Kim, Byeong-Teck Kang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>An 8-year-old neutered male Maltese dog was presented with 6 palpable cutaneous masses on the neck and thorax 1 y after the surgical excision of mast cell tumors (MCT) from the mid-thoracic and right axillary regions. Before chemotherapy, the sum of the masses' diameters was 19.0 cm. <sup>18</sup>F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) revealed hypermetabolic lesions within the skin overlying the ventral thorax, bilateral prescapular lymph nodes, and right axillary lymph node. The dog was diagnosed with MCT recurrence and treated with combination chemotherapy comprising imatinib, vinblastine, and prednisolone. After completion of 2 16-week chemotherapy regimens, the sum of the masses' diameters decreased to 3.6 cm. For assessment of the chemotherapy response and guidance for subsequent therapeutic plans, follow-up FDG-PET/CT was undertaken 25 d after completion of the 2nd chemotherapy regimen. It demonstrated a reduction in FDG uptake in all areas compared with that on the initial scan, except for the middle thoracic mass. After follow-up FDG-PET/CT, a 3rd chemotherapy regimen was implemented, and the dog died 416 d after the initiation of chemotherapy. There are no reports of a combination chemotherapy with imatinib, vinblastine, and prednisolone for treating canine cutaneous MCT. This case highlighted the potential therapeutic use of this combination chemotherapy for recurrent canine MCTs. Furthermore, this report indicates that FDG-PET/CT may be useful for assessing malignancy, evaluating chemotherapy responses, and establishing treatment plans for canine cutaneous MCTs. Key clinical message: Combination chemotherapy of imatinib, vinblastine, and prednisolone is a potential therapeutic regimen for recurrent cutaneous MCTs in dogs. In addition, FDG-PET/CT may be a potentially useful tool for assessing malignancy, evaluating chemotherapy responses, and guiding further therapeutic decisions.</p>","PeriodicalId":9429,"journal":{"name":"Canadian Veterinary Journal-revue Veterinaire Canadienne","volume":"66 7","pages":"755-763"},"PeriodicalIF":1.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261935/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Veterinary Journal-revue Veterinaire Canadienne","FirstCategoryId":"97","ListUrlMain":"","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
An 8-year-old neutered male Maltese dog was presented with 6 palpable cutaneous masses on the neck and thorax 1 y after the surgical excision of mast cell tumors (MCT) from the mid-thoracic and right axillary regions. Before chemotherapy, the sum of the masses' diameters was 19.0 cm. 18F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) revealed hypermetabolic lesions within the skin overlying the ventral thorax, bilateral prescapular lymph nodes, and right axillary lymph node. The dog was diagnosed with MCT recurrence and treated with combination chemotherapy comprising imatinib, vinblastine, and prednisolone. After completion of 2 16-week chemotherapy regimens, the sum of the masses' diameters decreased to 3.6 cm. For assessment of the chemotherapy response and guidance for subsequent therapeutic plans, follow-up FDG-PET/CT was undertaken 25 d after completion of the 2nd chemotherapy regimen. It demonstrated a reduction in FDG uptake in all areas compared with that on the initial scan, except for the middle thoracic mass. After follow-up FDG-PET/CT, a 3rd chemotherapy regimen was implemented, and the dog died 416 d after the initiation of chemotherapy. There are no reports of a combination chemotherapy with imatinib, vinblastine, and prednisolone for treating canine cutaneous MCT. This case highlighted the potential therapeutic use of this combination chemotherapy for recurrent canine MCTs. Furthermore, this report indicates that FDG-PET/CT may be useful for assessing malignancy, evaluating chemotherapy responses, and establishing treatment plans for canine cutaneous MCTs. Key clinical message: Combination chemotherapy of imatinib, vinblastine, and prednisolone is a potential therapeutic regimen for recurrent cutaneous MCTs in dogs. In addition, FDG-PET/CT may be a potentially useful tool for assessing malignancy, evaluating chemotherapy responses, and guiding further therapeutic decisions.
期刊介绍：
The Canadian Veterinary Journal (CVJ) provides a forum for the discussion of all matters relevant to the veterinary profession. The mission of the Journal is to educate by informing readers of progress in clinical veterinary medicine, clinical veterinary research, and related fields of endeavor. The key objective of The CVJ is to promote the art and science of veterinary medicine and the betterment of animal health.
A report suggesting that animals have been unnecessarily subjected to adverse, stressful, or harsh conditions or treatments will not be processed for publication. Experimental studies using animals will only be considered for publication if the studies have been approved by an institutional animal care committee, or equivalent, and the guidelines of the Canadian Council on Animal Care, or equivalent, have been followed by the author(s).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
